Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Horn, Sarah
CAMELOT, NCT05590637: Comparing Antipsychotic Medications in LBD Over Time	Recruiting	4	94	US	Pimavanserin, Nuplazid, Quetiapine, Seroquel	The University of Texas Health Science Center at San Antonio, Alzheimer's Association	Parkinson's Disease Psychosis, Dementia With Lewy Bodies	08/25	02/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Horn, Sarah
CAMELOT, NCT05590637: Comparing Antipsychotic Medications in LBD Over Time	Recruiting	4	94	US	Pimavanserin, Nuplazid, Quetiapine, Seroquel	The University of Texas Health Science Center at San Antonio, Alzheimer's Association	Parkinson's Disease Psychosis, Dementia With Lewy Bodies	08/25	02/26
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26